Adenovirus-mediated expression of TIMP-1 and TIMP-2 in bone inhibits osteolytic degradation by human prostate cancer

✍ Scribed by Xiyun Deng; Guangchun He; Andrea Levine; Ya Cao; Chad Mullins

• Publisher: John Wiley and Sons
• Year: 2007
• Tongue: French
• Weight: 699 KB
• Volume: 122
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.23053

✦ Synopsis

Abstract

Matrix metalloproteinases (MMPs) are proteolytic enzymes that play critical roles in the pathogenesis of human cancers. Clinical trials using synthetic small molecule MMP inhibitors have been carried out but with little success. Tissue inhibitors of metalloproteinases (TIMPs) are endogenous inhibitors that block the extracellular matrix‐degrading activity of MMPs. Here, we investigated the possibilities of genetically modifying human bones with TIMPs to create a high‐TIMP bone microenvironment, which is hostile to metastatic prostate cancer cells using adenovirus‐mediated gene transfer technology and SCID‐hu end‐organ colonization mouse model. Two strategies were used to achieve bone‐specific TIMP expression: (i) ex vivo bone adenoviral infection followed by in vivo bone implantation; and (ii) ex vivo BMS cell infection followed by injection into in vivo implanted human fetal bones. PC‐3 prostate cancer cells were injected into human fetal bones 4 weeks after implantation in SCID mice. In vitro, adenovirus‐mediated expression of TIMP‐1 or TIMP‐2 in bone fragments inhibited MMP‐2 activity, bone turnover and prostate cancer cell‐induced proteolytic degradation as determined by gelatin zymography, calcium measurement and DQ protein quenched fluorescence assay, respectively. In vivo, immunohistochemistry confirmed TIMP‐2 expression in AdTIMP‐2‐infected bone implants 4 weeks after implantation in SCID mice. Mice receiving AdTIMP‐treated bone fragments showed significantly reduced PC‐3‐induced osteolysis, osteoclast recruitment and bone turnover in the implanted bones. We propose that adenoviral gene transfer of TIMP‐1 and TIMP‐2 can prevent the proteolytic activity of prostate cancer cells in bone and that enhancing anti‐proteolytic defense mechanisms in target organs represents a promising form of prostate cancer gene therapy. © 2007 Wiley‐Liss, Inc.